ARCT Arcturus Therapeutics Holdi...

Nasdaq arcturusrx.com


$ 5.91 $ -0.14 (-2.32 %)    

Thursday, 20-Nov-2025 15:59:58 EST
QQQ $ 584.62 $ -14.20 (-2.37 %)
DIA $ 458.30 $ -3.66 (-0.79 %)
SPY $ 652.19 $ -10.10 (-1.52 %)
TLT $ 89.30 $ 0.35 (0.39 %)
GLD $ 375.00 $ -0.11 (-0.03 %)
$ 5.9
$ 6.23
$ 5.88 x 29
$ 5.91 x 200
$ 5.85 - $ 6.38
$ 5.85 - $ 24.17
1,013,006
na
167.63M
$ 2.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-06-2025 01-01-1970 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-05-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 03-14-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-29-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-10-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-08-2020 03-31-2020 10-Q
24 03-16-2020 12-31-2019 10-K
25 11-08-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-maintains-neutral-on-arcturus-therapeutics-lowers-price-target-to-9

Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target...

 piper-sandler-maintains-overweight-on-arcturus-therapeutics-lowers-price-target-to-72

Piper Sandler analyst Yasmeen Rahimi maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight and lowers the price ta...

 hc-wainwright--co-maintains-neutral-on-arcturus-therapeutics-lowers-price-target-to-9

HC Wainwright & Co. analyst Andrew S. Fein maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the p...

 arcturus-therapeutics-q3-eps-049-beats-090-estimate-sales-17151m-miss-21196m-estimate

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of...

 hc-wainwright--co-downgrades-arcturus-therapeutics-to-neutral-lowers-price-target-to-12

HC Wainwright & Co. analyst Andrew S. Fein downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral and lowers...

 citigroup-downgrades-arcturus-therapeutics-to-neutral-lowers-price-target-to-12

Citigroup analyst Yigal Nochomovitz downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral and lowers the price ...

 arcturus-investigational-inhaled-therapy-lacks-meaningful-lung-function-improvement-analyst-notes-mixed-picture

Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but...

 btig-maintains-buy-on-arcturus-therapeutics-lowers-price-target-to-23

BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $48 to...

 guggenheim-downgrades-arcturus-therapeutics-to-neutral

Guggenheim analyst Seamus Fernandez downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral.

 arcturus-announces-interim-results-from-ongoing-phase-2-clinical-trial-of-arct-032-investigational-inhaled-mrna-therapy-for-people-with-cystic-fibrosis

ARCT-032 generally safe and well toleratedMeaningful trends of clinical activity observed via high resolution CT scansAfter onl...

Core News & Articles

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

 cathie-woods-ark-bets-big-on-solana-treasury-play-makes-162m-investment-in-brera-holdings-as-stock-explodes-225

On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and b...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION